The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 105-109

  Estepp, Jeremie H ^a   Smeltzer, Matthew ^a   Reiss, Ulrike M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anticoagulant therapy; Coagulation; Hemostasis; Thrombosis

Indexed keywords

ENOXAPARIN; HEPARIN;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM THROMBOSIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; VENOUS THROMBOSIS;

EID: 84861218130     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23396     Document Type: Article

References (30)

1. Chalmers EA. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 2006; 118: 3-12.
2. Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: A systematic review and meta-analysis of observational studies. Circulation 2008; 118: 1373-1382.
3. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-1257.
4. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149: 209-220.
5. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 2003; 362: 523-526.
6. Kuhle S, Massicotte MP, Chan A, et al. Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service. J Thromb Haemost 2004; 92: 722-728.
7. Nowak-Göttl U, Kurnik K, Krümpel A, et al. Thrombophilia in the young. Hamostaseologie 2008; 28: 16-20.
8. Revel-Vilk S, Kenet G. Thrombophilia in children with venous thromboembolic disease. Thromb Res 2006; 118: 59-65.
9. van Ommen CH, Heijboer H, Bnller HR, et al. Venous thromboembolism in childhood: A prospective two-year registry in The Netherlands. J Pediatr 2001; 139: 676-681.
10. Nowak-Gottl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: Two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76: F163-F167.
11. Monagle P, Adams M, Makelburg A, et al. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47: 763-766.
12. Revel-Vilk S, Sharathkumar A, Massicotte P, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: A longitudinal study by ultrasound. J Thromb Haemost 2004; 2: 42-46.
13. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107: 21-29.
14. Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006; 55: 850-855.
15. Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol/Oncol 2000; 22: 66-72.
16. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2009; 351: 1081-1088.
17. Nowak-Gottl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862.
18. Revel-Vilk S, Chan A, Bauman M, et al. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1: 915-921.
19. Van Ommen CH, Heijboer H, Van Den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: Congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1: 2516-2522.
20. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2008; 133: 454S-545S.
21. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
22. Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: A meta-analysis. JAMA 2005; 294: 706-715.
23. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: A prospective cohort study. J Pediatr 2000; 136: 439-445.
24. Merkel N, Gunther G, Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescenct patients. Acta Haematol 2006; 115: 230-236.
25. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children. Chest 2008; 133: 887S-968S.
26. Monagle P, Newall F, Campbell J. Anticoagulation in neonates and children: Pitfalls and dilemmas. Blood Rev 2010; 24: 151-162.
27. Schobess R, During C, Bidlingmaier C, et al. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: An open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006; 91: 1701-1704.
28. Streif W, Goebel G, Chan AKC, et al. Use of low molecular mass heparin (enoxaparin) in newborn infants: A prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 2003; 88: F365-F370.
29. Massicotte P, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133: 770-776.
30. Limdi NA, Beasley TM, Allison DB, et al. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. Blood Cells Mol Dis 2009; 37: 100-106.